• Overview
• Who Should Attend
• Speaking Faculty
• Agenda
• Download the Agenda
• IO360˚ Leadership Interviews
• 2021 Sponsors / Exhibitors
• Sponsors / Exhibitors
• Sponsorship / Exhibit Opportunities
• Partners / Media
• Event News
• Photo Gallery
• 2020 Speaker Presentations
• Testimonials
• IO360˚ Recap

Overview

IO360˚convened stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.

The 6th Annual Immuno-Oncology 360° Delivered Three Key Benefits:

1. Access to KOLs driving the science
2. Partnership opportunities with all stakeholders in Immuno-Oncology
3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology

Strategic Leadership

 

Immuno-Oncology 360° reported on the most current data and rapid advancements to help IO stakeholders:

Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof Partner to expand technology platforms to develop therapeutics at an accelerated rate Receive the latest pre-clinical, translational and clinical data from academia and industry Create and prioritize strategies targeted toward specific tumor types

Identify and gain a greater understanding of what assets are available for potential combinations Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more Obtain coverage on a wide range of emerging technologies

Dr Michel Sadelain, MSKCC delivered the Opening Keynote: CAR T Cell Therapy and the CD19 Paradigm at IO360° 2019.

Dr Laura Esserman, UCSF delivered a keynote on Evolving I-SPY 2 to Optimize Breast Cancer Outcomes at IO360° 2019.

Cancer Veteran Judy Perkins, the 1st person to be declared free of metastatic breast cancer after a course of Immunotherapy joined author Charles Graeber at IO360° 2019 to share her journey.

Dr Priti Hegde, Genentech leads a Next Generation Biomarker panel with Dr Dan Chen, IGM Biosciences, Dr Ian McCaffery, Janssen, Dr Alessandra Cesano, NanoString, Dr Theresa LaVallee, Parker Institute and Dr David Messina, Cofactor Genomics at IO360° 2019.

---

If you are interested in participating in the 7th Annual Immuno-Oncology 360° 2021 program, please contact us at service@tcfllc.org. Thank you.

Sincerely,​

Kate Woda Conference Director	Valerie Bowling Executive Director
Meredith Sands Executive Director, Business Development	Geeta Bachani Business Development Manager
Elizabeth Bard Business Development Manager	Bre Bugbee Marketing Manager
Adam Kolanko Business Development Manager	Meg Gould Senior Conference Planner

Testimonials

• "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

  - Roy Baynes, MD, PhD, Merck

• "I really enjoyed it and connecting with some really interesting and inspiring people with whom I'm sure this is just the beginning of long standing interactions."

  - Jacqueline Karmel, Roche

• "Thank you again for the amazing invitation, it was truly my pleasure to be able to participate in the excellent event you organized."

  - Christine Ward, BMS

• "IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"

  - Jim Mansfield, PerkinElmer

• "Congratulations again on the excellent program for the Immuno-Oncology 360° meeting. It was truly well coordinated and the topics were fantastic!"

  - Gilson Baia, PhD, Champions Oncology

• "Really good, well-rounded and novel content. Congratulations on filling the house beyond capacity and for securing such an impressive speaking faculty."

  - Eileen Daniels, Nektar Therapeutics

• "Thank you for a great conference!"

  - Elena Spanjaard, Pfizer

• "Your team did a wonderful job in putting together an interesting and relevant program."

  - Lew Bender, Intensity Therapeutics

• "It was a great conference and I was happy to be a part of it."

  - Anna Pavlick, DO, MD, NYU Cancer Center